Patheon’s Parent Company DPx Holdings To Acquire Gallus BioPharmaceuticals
DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, has agreed to acquire Gallus BioPharmaceuticals, LLC, a biologics contract manufacturer. Following the transaction, Patheon's biologic drug substance business, a unit of DPx Holdings, will include four facilities in Europe, Australia, and North America and include 550 employees globally.
DPx Holdings is the parent company of Patheon, DSM Fine Chemicals, and Banner Life Sciences. The Patheon pharma services business provides commercial manufacturing, pharmaceutical product development services for solid and sterile dosage forms, and biologic and chemical drug-substance development and manufacturing. The addition of Gallus BioPharmaceuticals provides Patheon with additional biologics capabilities, namely process development as well as clinical- and commercial-scale manufacturing of mammalian cell-culture derived products. Patheon gained drug-substance biologics capability with the merger of Patheon and DSM Pharmaceutical Products to form DPx Holdings, a deal which was completed in March 2014, and the subsequent integration of the Biosolutions and Biologics businesses of DSM Pharmaceutical Products into Patheon.
Once the transaction is complete the two Gallus sites in St. Louis, Missouri and Princeton, New Jersey will be Patheon’s first biologic drug substance sites in the US and will complement the two existing sites in Groningen, the Netherlands and Brisbane, Australia. Three of the four global sites each have nearly three decades of mammalian cell-culture experience while the fourth site in Brisbane was opened within the last year.
Subject to receipt of regulatory approvals, the transaction is expected to close in the fourth quarter of 2014.
See earlier related story, “Executive Insights: DPx Holdings B.V. on the Road to Integration”